Aprinoia Therapeutics (Aprinoia Therapeutics) Liabilities-to-Assets : 6.66 (As of Jun. 2023)

View and export this data going back to 2050. Start your Free Trial

What is Aprinoia Therapeutics Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Aprinoia Therapeutics's Total Liabilities for the quarter that ended in Jun. 2023 was $96.41 Mil. Aprinoia Therapeutics's Total Assets for the quarter that ended in Jun. 2023 was $14.48 Mil. Therefore, Aprinoia Therapeutics's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2023 was 6.66.

Aprinoia Therapeutics Liabilities-to-Assets Historical Data

The historical data trend for Aprinoia Therapeutics's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprinoia Therapeutics Liabilities-to-Assets Chart

Aprinoia Therapeutics Annual Data

Trend

Dec21

Dec22

Liabilities-to-Assets

4.81

14.37

Aprinoia Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23
Liabilities-to-Assets	4.81	-	14.37	6.66

Competitive Comparison of Aprinoia Therapeutics's Liabilities-to-Assets

For the Biotechnology subindustry, Aprinoia Therapeutics's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aprinoia Therapeutics's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aprinoia Therapeutics's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Aprinoia Therapeutics's Liabilities-to-Assets falls into.

Aprinoia Therapeutics Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Aprinoia Therapeutics's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Liabilities-to-Assets (A: Dec. 2022 )	=	Total Liabilities	/	Total Assets
	=	81.093	/	5.643
	=	14.37

Aprinoia Therapeutics's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2023 is calculated as

Liabilities-to-Assets (Q: Jun. 2023 )	=	Total Liabilities	/	Total Assets
	=	96.408	/	14.476
	=	6.66

Aprinoia Therapeutics (NAS:APRI) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.

Aprinoia Therapeutics Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Aprinoia Therapeutics's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Aprinoia Therapeutics (Aprinoia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprinoia Therapeutics Inc (NAS:APRI) » Definitions » Liabilities-to-Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.

Aprinoia Therapeutics (Aprinoia Therapeutics) Headlines

No Headlines